Healthcare Select Sector SPDR (XLV) 67.63 $XLV S&P 500

New Post Public Reply Private Reply Replies (0) Message Board

Oct 22, 2015 at 1:52 PM

Healthcare Select Sector SPDR (XLV) 67.63 $XLV

S&P 500 ETFs Vs Ex-Sector ETFs
Zacks Equity Research - Zacks Investment Research - Tue Oct 20, 10:38AM CDT
Inside the head-to-head comparison between the S&P 500 ETF and ProShares new ex-sector ETFs.
SPXV: 42.05 (+0.17), SPXE: 41.77 (-0.04), SPXT: 41.41 (unch), SPY: 205.16 (+3.31), XLK: 42.66 (+0.96), SPXN: 41.51 (unch), XLF: 23.93 (+0.43), XLV: 67.63 (-0.66), XLE: 68.41 (+1.20)

Breakthrough Biotech ETF on Cancer Treatment
Zacks Equity Research - Zacks Investment Research - Mon Oct 19, 12:54PM CDT
Want exposure to an innovative biotech field? The first cancer immunotherapy ETF (CNCR) is now within your reach.
BBP: 28.90 (+0.08), BBC: 26.48 (-0.36), SBIO: 27.71 (-0.36), CNCR: 26.19 (-0.03), IBB: 303.59 (-0.87), XLV: 67.63 (-0.66)

Obamacare Lifting Demand for Services Premier Has to Offer
at The Street - Fri Oct 16, 4:20PM CDT
Premier CEO Susan DeVore says her health care company is beating the market.
PINC: 33.81 (-1.89), XLV: 67.63 (-0.66)

UnitedHealth Solid Q3 Put These ETFs in Focus
Sweta Killa - Zacks Investment Research - Fri Oct 16, 9:49AM CDT
Investors may want to look at the these ETFs as UnitedHealth continued its long streak of earnings beat but saw rough trading.
IHF: 117.36 (-8.64), MTUM: 71.12 (+0.42), IYH: 141.94 (-1.70), UNH: 111.79 (-6.32), DIA: 174.44 (+2.96), FHLC: 32.21 (-0.42), VHT: 124.00 (-1.55), XLV: 67.63 (-0.66)

J&J Posts Mixed Q3 Bag: ETFs in Focus
Sweta Killa - Zacks Investment Research - Wed Oct 14, 8:57AM CDT
These ETFs are in focus given that Johnson & Johnson continued its long streak of earnings beat but missed on revenues.
IHE: 144.38 (-2.10), JNJ: 98.91 (+1.28), IYH: 141.94 (-1.70), GILD: 102.58 (+0.85), ABBV: 53.28 (-0.55), VHT: 124.00 (-1.55), XLV: 67.63 (-0.66)

These 3 Sector ETFs Got Crushed Last Quarter -- Will They Bounce Back?
Dan Caplinger, The Motley Fool - Motley Fool - Sun Oct 11, 10:40AM CDT
Investors had to deal with market volatility during the summer months, as a long-awaited correction in major market benchmarks finally happened on concerns about a slowdown in the global economy. As those who invest in sector-specific exchange-traded...
XLB: 44.55 (+1.09), XLV: 67.63 (-0.66), XLE: 68.41 (+1.20)

Correction in Health Care Stocks Remains in Full Force
at The Street - Thu Oct 08, 3:00PM CDT
Have we reached the point where something will be done about it?
CI: 131.27 (-5.34), ANTM: 137.61 (-5.18), HCA: 64.87 (-6.33), XBI: 64.03 (-0.30), UNH: 111.79 (-6.32), IBB: 303.59 (-0.87), XLV: 67.63 (-0.66)

5 Sector Favorites for Q3 Earnings & Their Hot ETFs
Sweta Killa - Zacks Investment Research - Thu Oct 08, 10:10AM CDT
These sector ETFs are expected to be the winners this earnings season.
DHI: 31.04 (-0.29), JNJ: 98.91 (+1.28), LEN: 51.79 (-0.30), JPM: 63.41 (+1.35), PFE: 33.17 (-0.29), ITB: 27.72 (-0.17), CARZ: 36.90 (+0.49), WFC: 54.32 (+1.20), BRK.B: 136.39 (+3.17), XLF: 23.93 (+0.43), IYT: 148.43 (+2.57), XLV: 67.63 (-0.66)

How to Trade 10 Key Sector ETFs Amid This Correction
at The Street - Thu Oct 01, 12:30PM CDT
Given neutral to negative technicals for all sectors, investors should continue to employ the strategy of “selling on strength” which has been in play since mid-year.
XLB: 44.55 (+1.09), XLP: 50.81 (+0.98), XLY: 79.20 (+0.99), XLK: 42.66 (+0.96), XLI: 54.50 (+1.52), IYT: 148.43 (+2.57), XLU: 45.47 (+0.60), XLF: 23.93 (+0.43), XLV: 67.63 (-0.66), XLE: 68.41 (+1.20)

Health Care Stocks: Not Looking So Good
at The Street - Mon Sep 28, 3:40PM CDT
The Health Care SPDR ETF chart shows a failed rally to the underside of the 200-day moving average: A classic sell signal.
XLV: 67.63 (-0.66)

Health Care Stocks: You Don't Look So Good
at The Street - Mon Sep 28, 3:05PM CDT
The Health Care SPDR ETF chart shows a failed rally to the underside of the 200-day moving average: a classic sell signal.
JNJ: 98.91 (+1.28), PFE: 33.17 (-0.29), XLV: 67.63 (-0.66)

'Fast Money' Recap: Nike Shows China's Consumers Are Still Buying
at The Street - Sat Sep 26, 4:00AM CDT
The trading panel discussed the state of the biotech sector, whether Caterpillar is an indicator of China's economic health and whether Coke is it.
SBUX: 61.52 (+0.99), KO: 43.49 (+1.30), SPY: 205.16 (+3.31), NKE: 131.30 (-1.17), GILD: 102.58 (+0.85), MRK: 50.90 (+0.31), FCX: 12.04 (+0.09), IBB: 303.59 (-0.87), CAT: 71.28 (+1.61), AAPL: 114.92 (+1.16), XLV: 67.63 (-0.66), CELG: 116.60 (+0.68)

Stocks Close Lower as Biotech Suffers Worst Week in Four Years
at The Street - Fri Sep 25, 3:01PM CDT
Stocks make a dramatic turn in the closing hour of trading Friday as volatile, high-momentum health care stocks fall after trouble earlier in the week.
VRX: 98.90 (-19.71), GE: 29.64 (+0.79), NKE: 131.30 (-1.17), BBRY: 7.16 (+0.08), PFE: 33.17 (-0.29), IBB: 303.59 (-0.87), CELG: 116.60 (+0.68), XLV: 67.63 (-0.66), BBBY: 58.58 (+0.86), GS: 183.64 (+3.94), JPM: 63.41 (+1.35), GILD: 102.58 (+0.85), MRVL: 9.11 (+0.02), PIR: 7.36 (-0.17), GOOGL: 681.48 (+9.68)

Stocks Lose Gains as Health Care Stocks Fall
at The Street - Fri Sep 25, 1:59PM CDT
Stocks make a dramatic turn into negative territory near the end of the session as volatile, high-momentum health care stocks fall.
VRX: 98.90 (-19.71), NKE: 131.30 (-1.17), PFE: 33.17 (-0.29), BBRY: 7.16 (+0.08), IBB: 303.59 (-0.87), CELG: 116.60 (+0.68), XLV: 67.63 (-0.66), BBBY: 58.58 (+0.86), GS: 183.64 (+3.94), JPM: 63.41 (+1.35), GILD: 102.58 (+0.85), MRVL: 9.11 (+0.02), PIR: 7.36 (-0.17), GOOGL: 681.48 (+9.68)

Stocks Recover From Lows in Final Hour of Trading
at The Street - Thu Sep 24, 6:58PM CDT
Stocks are off session lows by the final hour of trading on Thursday.
BIIB: 278.14 (+1.80), VRX: 98.90 (-19.71), PFE: 33.17 (-0.29), WOR: 31.17 (+1.00), WMT: 58.82 (+0.18), IBB: 303.59 (-0.87), XLV: 67.63 (-0.66), CELG: 116.60 (+0.68), BIDU: 153.13 (+3.50), GILD: 102.58 (+0.85), SCS: 19.69 (+0.15), FUL: 37.59 (+0.63), CAT: 71.28 (+1.61), KBH: 13.71 (-0.57), MSFT: 48.66 (+1.46)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Moore Law Urges Millrose Investors: Join the Action

Is Millrose Playing a Risky Game? When I caught wind of this latest debacle with Millrose Properties, Inc. (NYSE: MRP), my gut reaction was a mix of curiosity and skepticism. Hunterbrook Media's report just blasted across the headlines, digging up some dirt on Millrose's recent financial maneuvers. Apparently, these cats have been busy buying homes to the tune of $200...

TilePix Expands into Walmart with Nail-Free Decor Launch

TilePix Makes Big Moves with Walmart TilePix is launching their new line of nail-free wall décor at Walmart—this ain’t your grandma’s wall art. This company's bringing their magnetic, nail-free wizardry to retail stores nationwide for the first time, and they’ve chosen a real heavyweight partner—Walmart. What comes in the package? Well, they’re dealing in...

AAI Rolls Out Agency Gauge: AI-Driven Insights Platform

Bringing Artificial Intelligence to the Insurance Table Affordable American Insurance (AAI) is shaking things up in the insurance world with their new tool, Agency Gauge. Picture this: you're running an independent agency, neck-deep in data, and this AI-powered marvel swoops in and turns those confusing numbers into actionable business insights. It's like having a wise...

DOCS Faces Investor Legal Battle for Alleged Misconduct

The DOCS Predicament: Investors Facing Class Action Doximity, Inc., trading as NYSE:DOCS, finds itself in hot water again as shareholders gear up for a legal skirmish over alleged securities fraud. Schall, Brown & Schwartz LLP, the firm rallying the shareholders, has fired the opening salvo, pointing fingers at Doximity for cooking the books about their Newsfeed’s...

Roof Inspections: Richmond's Key to Home Longevity

Inspect, Protect, and Forget Your Worries Homeowners in the Greater Richmond area wisely take to heart the old saying: an ounce of prevention is worth a pound of cure. But let's cut through the noise for a moment and zero in on a foundational truth: regular roof inspections are not a luxury—they're an absolute must. Roofing expert Seth Brown, from BNH Roofing, makes it...

AI-Designed Antivirals: A Brave New World

Pushing the Boundaries with AI in Drug Discovery It seems some smart folks over in South Korea are giving the pharma game a fresh twist, pitting artificial intelligence against viral invaders in a newfangled brawl. Professors from Korea University have managed to blend AI's computing prowess with good ol' lab doggedness to sniff out potential antiviral compounds. The...

Kansai Medical Ushers in New Era of Cancer Research

Breaking Ground in Cancer Treatment Trials I've seen some thrilling breakthroughs in my time following the pharmaceutical industry, but what Kansai Medical University and Daiichi Sankyo are doing elevates the game. They're rolling out the first patient dose of DS1025 in Osaka, Japan—a move that marks the onset of a global Phase 1 clinical trial. This is no ordinary...

2GenPen & LordCap Team Up: Game-Changer in ABS?

New Kids on the Structured Credit Block? Well, it looks like we're in for a ride with 2GenPen teaming up with Lord Capital to shake up the asset-backed securities (ABS) world. They're strutting their stuff by launching a strategic collaboration to boost credit analysis. Think of it as a power-up for ABS transactions—because nobody loves a murky credit rating. The Heart...

Ama La Vida's New Coaching: More Than a Financial Plan

Breaking the Retirement Myth Retirement ain't just about sailing off into the sunset with a fat wallet. What happens when the honeymoon period of the "golden years" ends and you're left pacing the floorboards, unsure of what comes next? Enter Ama La Vida's fresh approach to retirement coaching, tackling the side of retirement that's rarely spoken about: identity,...

Endava Faces Securities Fraud Lawsuit: Investor Implications

Endava in Hot Water Over Alleged Misleading Statements Alright, folks, gather around—there's a storm brewing over at Endava with shareholders mightier than the Greek gods, furrowing their brows with intent. You see, Schall, Brown & Schwartz LLP, a firm that practically eats legal challenges for breakfast, is beating the drums of a securities fraud lawsuit. Yep, I'm...